Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study-Reference-Cited by-同舟云学术

Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study

Published:2024-08-19 Issue:1 Volume:24 Page:
ISSN:1472-6823
Container-title:BMC Endocrine Disorders
language:en
Short-container-title:BMC Endocr Disord

Author:

Isogawa Masahiro,Makino Hisashi,Son Cheol,Nishimura Kunihiro,Hirata Takumi,Kasama Shu,Miyamoto Yoshihiro,Noguchi Michio,Kasahara Masato,Hosoda Kiminori

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12902-024-01690-6.pdf

Reference33 articles.

1. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23(10):1499–504.

2. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327–35.

3. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321:69–79.

4. Kuwata H, Okamoto S, Seino Y, Murotani K, Tatsuoka H, Usui R, et al. Relationship between deterioration of glycated hemoglobin-lowering effects in dipeptidyl peptidase-4 inhibitor monotherapy and dietary habits: Retrospective analysis of Japanese individuals with type 2 diabetes. J Diabetes Investig. 2018;9:1153–8.

5. Kaku K, Kiyosue A, Inoue S, Ueda N, Tokudome T, Yang J, et al. Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise. Diabetes Obes Metab. 2014;16:1102–10.